CHMP5 and COVID-19: This study has demonstrated that i.n. immunization or parenteral priming following i.n. boosting with an experimental COVID-19 vaccine, based on the SARS-CoV-2 Spike trimer and formulated with a novel adjuvant, is an effective approach for inducing local antibody and T cell responses in the respiratory tract.